Foghorn Therapeutics Inc. — Form 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. filed a Current Report on Form 8-K dated June 8, 2022. The filing concerns Regulation FD disclosure of an investor presentation dated June 2022. Foghorn is a Delaware corporation headquartered in Cambridge, Massachusetts, and its common stock trades on The Nasdaq Global Market under the symbol FHTX.
Financial Metrics
The filing does not provide financial statements or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics. The filing is limited to furnishing an investor presentation as Exhibit 99.1.
Material Changes Versus Prior Period
The filing does not report material changes in financial performance, operations, capital structure, or liquidity versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- The company furnished an investor presentation dated June 2022 for use in meetings with or presentations to investors.
- The filing text does not provide the presentation’s contents, including any guidance, pipeline updates, management commentary, risks, contingencies, or unusual items.
- The information is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Obtain and review Exhibit 99.1, the June 2022 investor presentation, because its substantive contents are not included in the filing text.
- Verify any financial, clinical, pipeline, partnership, financing, or outlook information presented in Exhibit 99.1 against subsequent SEC filings.
- Confirm that the investor presentation was furnished rather than filed and assess the implications for incorporation by reference and liability.